Innovative Catheter Lock Solution Introduced to Member Hospitals
Introducing Member hospitals to novel health care products that optimize patient care is the goal of Mohawk Medbuy’s (MMC’s) Innovation LaunchPad Program. Our Innovation LaunchPad streamlines access to new, unique products and services that enhance patient care, improve patient and staff safety or provide process efficiencies.
Thousands of central line associated bloodstream infections (CLABSIs) are reported every year in Canada and result in significant financial costs to the health care system. Prevention is key to improving patient outcomes and enhancing care.
Through our Innovation LaunchPad, MMC recently introduced SterileCare’s KiteLock™ 4% Sterile Catheter Lock Solution, a new product designed to prevent CLABSIs, to our Members.
“The clinicians at our Member hospitals are extremely busy caring for patients and have limited opportunities to assess new and innovative products,” said Rosemary Frketich, MMC’s Director, Clinical Services & Quality Assurance. “MMC’s multidisciplinary team pre-screens new innovations on their behalf and, if they meet our criteria, we provide this information to our Members.”
SterileCare’s KiteLock™ 4% is such a product. The solution, which has antimicrobial, anticoagulant and antibiofilm properties, is instilled in the central line catheter to prevent infections, occlusions and biofilms.
Earlier this year, through the CAN Health Network, MMC Member hospital Hamilton Health Sciences (HHS) began using KiteLock™ 4% with a focus on decreasing central line infections with oncology patients. HHS is currently reviewing the data to determine the clinical outcomes. If a reduction in catheter complications is achieved, the hospital plans to continue using it with its oncology patients as well as extending it to additional patient populations.
Innovation is a driving force behind Mohawk Medbuy’s commitment to serving our Members and enhancing health care across Canada. Learn more about our Innovation LaunchPad Program here.